Drugs / Irsenontrine
Irsenontrine
also known as
E2027 · E-2027 MALEATE · ER-000592221- MAL · ER-592221-00 · ER-592221-12 · IRSENONTRINE MALEATE
Small molecule targets PDE9A via inhibition
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04023877 | Jul → Oct 2019 | Lewy body dementia | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02947711 | Oct → Nov 2016 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02873156 | Aug 2016 → Nov 2017 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02415790 | Jul 2015 → Jun 2016 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04764669 | Feb → Dec 2021 | Lewy body dementia, Parkinson disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03467152 | May 2018 → Apr 2020 | Lewy body dementia | Eisai Inc. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-07-19 | Eisai Inc. | Results LATEST DATA ON EISAI’S ALZHEIMER’S DISEASE / DEMENTIA PIPELINE TO BE PRESENTED AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2018 Thirteen presentations to be given including on Phase II study results of BAN2401 and elenbecestat eisai.com ↗
Phase 1 Multiple Ascending Dose (MAD) Study of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia with Lewy Bodies |
All press releases naming this drug 1 release
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irsenontrine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03467152 ↗ |
| Known as | E-2027 MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650368 ↗ |
| Known as | E2027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02415790 ↗ |
| Known as | ER-000592221- MAL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650368 ↗ |
| Known as | ER-592221-00 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650368 ↗ |
| Known as | ER-592221-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650368 ↗ |
| Known as | IRSENONTRINE MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650368 ↗ |
| Action | Inhibit | “Irsenontrine (E2027) is a potent and selective PDE9 inhibitor” PMID 42026627 ↗ Apr 20261“Phosphodiesterase 9A inhibitor” CHEMBL4650368 ↗ |
| Modality | Small molecule | — CHEMBL4650368 ↗ |
| Route | Oral | “E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A” NCT02415790 ↗ |
| Target | PDE9A | “Phosphodiesterase 9A inhibitor” CHEMBL4650368 ↗ |